At the news
? BULLISHIMPACT 4/10 COURT-RULING filed Aug 16, 2026 at 20:00 ET
Sanofi won dismissal with prejudice of a product liability lawsuit over its drug Rezurock (belumosudil). The court granted the motion to dismiss under Rule 12(b)(6), finding the claims were time-barred and preempted by federal law, and denied leave to amend. This removes a small litigation overhang with no material financial exposure for a $109.7B company, but the stock impact is negligible given the case's trivial size and the company's market cap.
- Sanofi (SNY) won dismissal with prejudice of a product liability lawsuit over Rezurock (belumosudil) in the Eastern District of California.
- The court found the claims were time-barred under California's two-year statute of limitations and preempted by the FDCA.
- Plaintiff's complaint was dismissed without leave to amend, and the case is closed.
- No damages were awarded; the opinion does not state any amount sought by the plaintiff.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access